Segall Bryant & Hamill LLC Invests $1.97 Million in Viemed Healthcare, Inc. $VMD

Segall Bryant & Hamill LLC acquired a new stake in Viemed Healthcare, Inc. (NASDAQ:VMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 289,446 shares of the company’s stock, valued at approximately $1,965,000. Segall Bryant & Hamill LLC owned approximately 0.76% of Viemed Healthcare as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. raised its stake in Viemed Healthcare by 40.3% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 20,224 shares of the company’s stock valued at $141,000 after purchasing an additional 5,807 shares during the last quarter. SummerHaven Investment Management LLC acquired a new position in shares of Viemed Healthcare in the third quarter valued at approximately $828,000. Campbell & CO Investment Adviser LLC boosted its position in Viemed Healthcare by 13.9% during the third quarter. Campbell & CO Investment Adviser LLC now owns 75,216 shares of the company’s stock worth $511,000 after acquiring an additional 9,154 shares during the last quarter. Penbrook Management LLC boosted its position in Viemed Healthcare by 51.3% during the third quarter. Penbrook Management LLC now owns 272,328 shares of the company’s stock worth $1,849,000 after acquiring an additional 92,308 shares during the last quarter. Finally, Wasatch Advisors LP grew its stake in Viemed Healthcare by 18.4% in the 2nd quarter. Wasatch Advisors LP now owns 1,546,010 shares of the company’s stock worth $10,683,000 after acquiring an additional 240,346 shares during the period. Hedge funds and other institutional investors own 74.24% of the company’s stock.

Analyst Ratings Changes

VMD has been the topic of a number of recent analyst reports. Wall Street Zen raised Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Viemed Healthcare in a research report on Monday, December 29th. Finally, Zacks Research raised Viemed Healthcare to a “hold” rating in a research note on Thursday, January 8th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold”.

Viemed Healthcare Trading Down 7.5%

Shares of VMD opened at $8.40 on Friday. The company has a current ratio of 1.13, a quick ratio of 1.01 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $319.35 million, a P/E ratio of 22.70 and a beta of 1.23. The stock’s fifty day simple moving average is $7.88 and its 200 day simple moving average is $7.20. Viemed Healthcare, Inc. has a twelve month low of $5.93 and a twelve month high of $9.20.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. The firm had revenue of $76.18 million during the quarter, compared to the consensus estimate of $77.70 million. Viemed Healthcare had a return on equity of 10.82% and a net margin of 5.53%.

Viemed Healthcare Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.